
Opinion|Videos|November 18, 2015
Dr. Andre Goy on Future Treatments for Patients With Diffuse Large B-Cell Lymphoma
Author(s)Andre Goy, MD
Andre Goy, MD, MS, chief, John Theurer Cancer Center's Division of Lymphoma, talks about the emerging novel therapies in diffuse large B-cell lymphoma (DLBCL).
Advertisement
Andre Goy, MD, MS, chief, John Theurer Cancer Center Division of Lymphoma, talks about the emerging novel therapies in diffuse large B-cell lymphoma (DLBCL).
Goy says that some of the upcoming novel agents showing promise are bortezomib, both as a single agent and in conjunction with R-CHOP chemotherapy, as well as ibrutinib. Both ibrutinib and bortezomib showed great promise in phase II clinical trials and will be going on to phase III trials to determine their viability as treatments.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Priority Review to Dato-DXd First-Line Metastatic TNBC
2
FDA Accepts NDA of Zanzalintinib Combo for Pretreated Metastatic CRC
3
Gemogenovatucel-T Triples Overall Survival in High-Risk HRP Ovarian Cancer
4
FDA Oncology Update January 2026: New Horizons in Precision Medicine
5



















